Aurobindo Pharma to manufacture, supply HIV treatment cabotegravir across 133 countries
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-07-15 12:16 GMT | Update On 2025-07-15 12:16 GMT
Advertisement
New Delhi: Hyderabad-based drugmaker Aurobindo Pharma will produce and supply Cabotegravir, a long-acting injectable HIV treatment, across 133 countries, including several low and middle-income markets.
The treatment allows patients to receive just one injection every one or two months, providing an alternative to daily pills.
The company has been selected as one of the generic manufacturers under the expanded voluntary licensing agreement between the Medicines Patent Pool (MPP) and ViiV Healthcare, the company said in a statement.
This update now includes long-acting cabotegravir (CAB LA) for HIV treatment, in addition to its earlier use for prevention only.
The treatment offers an alternative to daily pills, allowing patients to receive just one injection every one or two months.
According to PTI, Aurobindo Pharma Vice Chairman & Managing Director K Nithyananda Reddy said, "We are privileged to be part of the sub-license expansion from MPP and ViiV to develop, manufacture, and distribute generic CAB LA in select markets for the treatment of HIV-1, in addition to the voluntary licence for PrEP."
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.